197,000 UK lives saved thanks to breast cancer advances
Almost 200,000 UK deaths from breast cancer have been averted since the late 80s, according to a new report.
Experts said that changes in how cancer is detected, diagnosed and treated have 'all been essential to these improvements'.
Overall, 1.5 million cancer deaths in the UK have been prevented since 1989, according to a new study predicting European cancer deaths in 2025.
But there will still be 173,300 cancer deaths overall in the UK this year, academics said.
Most cancer deaths among men in the UK in 2025 will be due to bowel; lung and prostate cancers.
While most cancer deaths among UK women will be due to bowel; lung and breast cancers.
Breast cancer deaths in the UK in 2025 will be lower than those observed in 2020 – with 11,400 women expected to die from breast cancer this year compared to 11,547 deaths in 2020.
The UK is also estimated to buck the trend when it comes to breast cancer deaths among elderly women – with deaths among over 80s attributed to breast cancer expected to rise in many European countries but fall in the UK.
Carlo La Vecchia, professor of medical statistics and epidemiology at the University of Milan in Italy, said: 'Elderly women are not covered by screening and probably are less favourably affected by the substantial advances in breast cancer management, including improvements in chemo and hormone therapy, but also in radiotherapy and surgery.
'The increased prevalence of overweight and obesity over the last few decades in most of northern and central Europe has led to an increased risk of breast cancer.
'In the elderly, this has not been counter-balanced by improved diagnosis and management. This accounts for the increased mortality in people aged 80 and over.'
In England, all women aged 50 to 71 are invited for breast cancer screening every three years.
Prof La Vecchia added: 'We estimate that between 1989 and 2025, 373,000 breast cancer deaths have been avoided in the EU and 197,000 in the UK.
'Most of these are due to improved management and therapy, but 25-30% are likely to be attributable to more widespread screening and early diagnosis.
'Given that breast cancer is now a largely curable cancer that requires modern integrated approaches, it is essential that all diagnoses of breast cancer are referred to comprehensive cancer centres, which can offer the complete range of therapies that might be required.
'As indicated by the unfavourable trends in elderly women, control of overweight and obesity is a priority now, not only for cardiovascular diseases, but also for cancer, including breast cancer.'
Commenting, Jon Shelton, Cancer Research UK's head of cancer intelligence, said: 'Breast cancer mortality rates have fallen substantially in the UK since the early 1970s, and it's extremely positive to see that trend continue.
'Breakthroughs in how we detect, diagnose and treat the disease have all been essential to these improvements.
'Studies like this showcase the power of science, and if the UK Government's upcoming national cancer plan for England prioritises reform and investment in cancer services and getting research and innovation into care, we'll see even more improvements for people affected by cancer.'
Dr Kotryna Temcinaite, head of research communications and engagement at Breast Cancer Now, said: 'It's reassuring that this research suggests that nearly 197,000 deaths from breast cancer have been avoided in the UK in the last 37 years across women of all ages.
'This could be due to a combination of increased awareness and improvements in cancer detection and treatment. But the stark reality is that 11,500 women still die from this devastating disease each year in the UK, making research into how we better diagnose and treat breast cancer more needed than ever.
'Most breast cancers (80%) occur in women aged over 50, and a quarter (25%) of cases are diagnosed in women aged 75 and over.
'It's crucial that all women regularly check their breasts and get to know their 'normal'.'
Dame Cally Palmer, national cancer director at NHS England, said: 'It's incredibly encouraging that deaths from breast cancer in the UK are continuing to fall as a result of improved early diagnosis and treatment.
'We know a third of women don't take up their invites for the scans which can detect cancer earlier, when treatment has the best chance of success – so I'd urge anyone who receives an invite to book a potentially life-saving appointment for NHS breast cancer screening.'
The new review, by a team of international researchers, also predicts small reductions in lung cancer deaths for both men and women in the UK.
But bowel cancer deaths are expected to increase from the absolute numbers in 2020, according to the new study, which has been published in the journal Annals of Oncology.
Pancreatic cancer deaths are also expected to rise, according to the estimates.
Prof La Vecchia said: 'Trends in cancer mortality continue to be favourable across Europe, however, there are a few negative indications – these include deaths from bowel cancer in people younger than 50, which have started to increase in the UK and several central and northern Europe countries, mainly due to increased prevalence of overweight and obesity in the young who are not covered by colorectal cancer screening.
'In addition, death rates from pancreatic cancer are not decreasing in the EU, and it is now the fourth cause of cancer death in Europe after lung, colorectal and breast cancer.
'Death rates from lung cancer are starting to level off but not yet to decrease in EU women. The trends in pancreatic and female lung cancer underline the urgency of implementing stricter tobacco control across Europe.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
No drug price pledges in talks with US government, Pfizer CEO says
STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Newel Health obtains EU MDR for blood pressure management platform
Amid the growing prevalence of hypertension in the EU, Italian health tech Newel Health has secured a CE mark for its Amicomed platform under the EU's Medical Device Regulation (EU MDR), enabling it to support the management of high blood pressure. Compatible with blood pressure monitors including Apple Health and Google Fit, the smartphone app-based platform captures structured blood pressure data and translates it into 'clinically meaningful' insights, Newel Health stated, and offers personalised feedback towards high blood pressure management based on real-world data. The platform's features include medication reminders to improve adherence, and personalised lifestyle and dietary recommendations based on a user's clinical profile. The capabilities are supported by Amicomed's architecture. Developed by Newel Health, the proprietary platform uses artificial intelligence (AI)-based predictive models to improve behavioural segmentation, sustain engagement, and adapt interventions based on an individual's profile. A 2023 report by GlobalData forecasts that AI platforms in healthcare will reach a valuation of $18.8bn by 2027. Newel Health CEO, Ervin Ukaj commented: "We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach.' Ukaj added that Newel intends to pursue 'scalable growth' by seeking further partnerships with public and private healthcare stakeholders. Systemic hypertension is a key risk factor for chronic disease burden, and a known precursor for cardiovascular diseases (CVDs) including atherosclerotic cardiovascular disease, with research indicating that hypertension in the EU is on the rise. A European Commission (EC) survey from 2019 found that 22% of individuals aged 15 and above reported having received a high blood pressure diagnosis from a medical professional, while a 2023 report by the World Health Organization (WHO) estimates that the number of adults with hypertension in the European region and the Americas rose from 302 million in 1990 to 427 million in 2019 – reflecting a 41% rise. All medical device manufacturers marketing products in the EU must fall in line with the dictates of the EU MDR regulation by 2028. Introduced in 2017 and coming into its 'first phase' of effect in 2021, the EU MDR is promulgated as a means to centralise competencies at the EU level. While well-intentioned, some observers have deemed the regulation's roll out a 'disaster', with concerns around a perceived lack of clarity, and the regulation's overall scope and complexity – factors that have proven particularly challenging for companies with existing device on the European market. "Newel Health obtains EU MDR for blood pressure management platform" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
TeleTracking and Palantir partner for operational decision-making in healthcare
TeleTracking Technologies has collaborated with Palantir Technologies to enhance operational decision-making in healthcare. This strategic partnership is set to offer long-term value to healthcare providers worldwide by integrating TeleTracking's Operations IQ platform with the analytics and Palantir's AI-driven operating system, Palantir Foundry and AIP. Combining the operational workflow expertise of TeleTracking with the decision intelligence capabilities of Palantir, the partnership will enable caregivers to integrate and analyse various data types. This includes clinical, operational, financial, workforce, and third-party information. The goal is to use predictive forecasting and demand modelling to manage capacity, staffing, and resources more efficiently. The partnership will facilitate transparency and almost instantaneous awareness of circumstances across different areas or systems, leading to the optimisation of crucial resources throughout the entire organisation. It will also enhance the movement of patients through operational command centres. The distinctive operational information provided by TeleTracking, together with the AI-native platform from Palantir, seeks to automate operational procedures, lessening the load on staff and caregivers while also enhancing patient care and financial results. Palantir CEO Alex Karp said: 'This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of, where we continue to move closer to a world where all hospitals and health systems are embracing, implementing, and operating with an AI-powered approach, helping to streamline operations allowing for increased focus on providing the best level of care.' Health systems, regardless of their sizes, benefit from improved operational coordination, multi-hospital system management, and strategic planning powered by data. The partnership is designed to tailor their response capability to changing patient requirements and help to achieve cost efficiency. Earlier this year, TeleTracking announced a five-year collaboration with European applied AI company Faculty. This partnership aims to bring AI-powered automation and predictive capabilities to health systems and hospitals. "TeleTracking and Palantir partner for operational decision-making in healthcare" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.